The Supreme Court of Canada has today granted AstraZeneca leave to appeal a Federal Court of Appeal decision, affirming a trial decision invalidating its patent relating to its successful esomeprazole drug (NEXIUM) for lack of utility.
The patent utility requirement in Canada has been the subject of controversy and debate. The appeal will present the Supreme Court with an opportunity to consider whether a promised utility doctrine properly exists, and the correct applicable standard for patent utility in Canada.
In AstraZeneca Canada Inc v Apotex Inc, 2014 FC 638, the trial judge found AstraZeneca’s Canadian Patent No. 2,139,653 claims novel and unobvious, and if valid would have been infringed by Apotex’s sale of its generic esomeprazole drug. The trial judge, however, found a “promise” of improved therapeutic profile, unmet at the filing date, to be “fatal” and held the patent invalid. The Federal Court of Appeal affirmed in 2015 FCA 158.
AstraZeneca is represented on the appeal by a team from Smart & Biggar, including Gunars Gaikis, Yoon Kang and Lynn Ing.
For further information, please contact a member of our firm’s Pharmaceutical group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Quebec Court finds price and revenue calculation provisions of amended PMPRB Regulations unconstitutional
The Quebec Superior Court issued its decision from a constitutional challenge to the PMPRB provisions of the Patent Act and the Regulations, including the amended Regulations.Read More -
Amendments to PMPRB Regulations will now be in force July 1, 2021
While scheduled to come into force on January 1, 2021 (see here), in recognition of the fact that the COVID-19 pandemic continues to challenge all stakeholders, the amendments to the Patented Medicine...Read More -
2020 Highlights in Canadian Life Sciences IP and Regulatory Law
In 2020, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law.Read More